Kornimate/medical-research-clean huggingface dataset:
women and risk of type 2 diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: this is a follow-up survey of women, 10-12 years after they were included in the population-based stork groruddalen study of pregnant women, primarily set up to study gestational diabetes and related health issues in pregnancy in a multiethnic population. the investigators will now update the information about the health status of these women to study the development of risk factors for type 2 diabetes and cardiovascular diseases.

the stork-groruddalen is a cohort study of 823 pregnant women. participation rate was high due to facilitation for ethnic minorities and data collection at the local health centres, set up to study ethnic differences in health to inform prevention strategies to reduce these differences. the investigators have published many papers from this well charatertized cohort, about gestational diabetes and related health issues in pregnancy. participants have agreed to be contacted for subsequent follow-up surveys. the inivestigators are now planning a follow-up study of these woman during 2019-2022, to study trajectories for risk factors for type 2 diabetes and cardiovascular diseases such as bmi, blood pressure, lipids, behavioural factors, physical activity and mental health and other health issues. the investigators will collect selfreported information through questionnaires, perform clinical measurements and take blood samples and buccal swabs. collecting updated information about a range of health outcomes for women in this cohort will, together with already collected data, enable us to study the development of risk factors for type 2 diabetes and cardiovascular diseases in a life course perspective.

Eligibility criteria:
inclusion criteria: * previous participants in the stork g study still living in norway exclusion criteria: * moved out of norway

Keywords: prevention cardiovascular diseases physical activity ethnic differences in health risk factors
ltfu study of subjects with cervical sci who received ast-opc1

Conditions: Spinal Cord Injuries

Summary: this is a ltfu study for cervical sci subjects that were administered ast-opc1 cells in the main study ast-opc1-01.

study ast-opc1-02 is a phase 1/2a open-label, multi-center long term follow-up (ltfu) study for twenty-five (25) subjects with cervical sci that were administered ast-opc1 cells in the main dose-escalation study ast-opc1-01. the purpose of this study is to monitor long-term safety in subjects for 15 years post ast-opc1 administration.

Eligibility criteria:
inclusion criteria: * subjects who received ast-opc1 under study ast-opc1-01 * reconfirmation of consent for long-term follow-up exclusion criteria: •subjects who, for geographic or compliance reasons, are inappropriate candidates for participation in a long-term follow-up study in the opinion of the investigator
pancreatic adenocarcinoma in hospital

Conditions: Pancreatic Adenocarcinoma

Summary: few data are currently available in the literature on pancreatic adenocarcinoma in france. about 8,000 new cases each year in france. the 5-year survival for all stages combined is \<5%. this is the only digestive cancer in which mortality / incidence ratio is 98%. epidemiological characteristics at diagnosis, the impact on the survival of recent advances related to surgery, adjuvant chemotherapy and new standard forms of adjuvant chemotherapy (folfirinox) are mispriced in real life. the development of new drugs and the development of phase ii and iii require a better understanding of the state of this disease in the country. the main objective is to describe the characteristics of the pancreatic adenocarcinoma at diagnosis in france and make an inventory of diagnostic practices and support.


Eligibility criteria:
inclusion criteria: * living in france * pancreatic adenocarcinoma histologically or cytologically proven * primary diagnosis * agreed to participate exclusion criteria: * suspected pancreatic adenocarcinoma histologically or cytologically unproven * refused to participate

Keywords: pancreatic adenocarcinoma diagnosis treatment
efficacy of electroencephalography (eeg) neurofeedback (nf) for the treatment of anxiety disorder

Conditions: Anxiety Disorder; Healthy

Summary: the aim of this study is to assess the efficacy of electroencephalography (eeg) neurofeedback (nf) as an add-on treatment for the anxiety disorder. meanwhile, evaluate the effect of eeg-nf on cognitive function of anxiety patients. furthermore, the investigators will examine the changes in cortisol, gut microbiome and some biomarkers. the hypothesis of this study is that eeg-nf alleviate the anxiety symptoms and improve the cognitive function of anxiety disorder patients with regulating attention response.

this is a randomized, double-blind, sham-controlled study using electroencephalography (eeg) neurofeedback (nf) for 2-week treatment. participants were randomly assigned 1:1 to nf group or sham-control group. the nf group performed six nf sessions every other day in about two weeks. the feedback value of the nf group was about smr band, while in the control group was pseudo-random numbers. apart from studying the effects of eeg-nf on severity of anxiety and cognitive function, the secondary outcomes are to examine biomarkers related to inflammatory activity. scale assessments are performed before the initiation of treatment, week 1, week 2. the digit span test, go/no-go task collection of blood, excrement and saliva takes place at two time points, at the baseline, week 2.

Eligibility criteria:
inclusion criteria: * a current episode of anxiety diagnosed according to diagnostic and statistical manual of mental disorders, fifth edition (dsm-5) * age between 18 and 50 years * a total score of hamd ≥14 gad-7≥ 5 * participants are compliant with treatment according to the judgement of the treating clinician. * participant or guardian has to sign informed consent. the patients' guardians will sign the informed consent on behalf of the participants when the capacity of participants to consent is compromised. exclusion criteria: * history of alcohol or drug abuse; * severe somatic diseases including conditions such as kidney and liver failure, uncontrolled hypertension, cardiovascular, cerebrovascular and pulmonary disease, thyroid disease, diabetes, epilepsy and asthma. * use of anti-inflammatory medication for longer than 7 days in the last two months preceding the trial * use of immunosuppressive medication such as oral steroid hormones women in pregnancy or lactation period
tpf induction chemotherapy vs pf adjuvant chemotherapy combined with concurrent chemoradiotherapy in the treatment of locally advanced npc

Conditions: Locally Advanced Nasopharyngeal Carcinoma

Summary: through randomized controlled phase iii multicenter clinical trials, tpf induction chemotherapy vs. pf regimen adjuvant chemotherapy concurrently radiotherapy and chemotherapy for the treatment of locally advanced nasopharyngeal carcinoma: the efficacy, toxicity and quality of life, and further improvement survival rate and improve the quality of life.


Eligibility criteria:
inclusion criteria: 1. patients with newly histologically confirmed non-keratinizing (according to world health organization (who) histologically type). 2. clinical staged as iii，iva（according to the american joint committee on cancer(ajcc) 7th edition） 3. fertility women should ensure contraception during entry into the study. 4. age 18-69 years old. 5. karnofsky scale(kps)≥70. 6. adequate marrow: leucocyte count ≥4000/μl, hemoglobin ≥90g/l and platelet count ≥100000/μl. 7. normal liver function test: alanine aminotransferase (alt)、aspartate aminotransferase (ast) \<1.5×upper limit of normal (uln) concomitant with alkaline phosphatase (alp) ≤2.5×uln, and bilirubin ≤uln. 8. adequate renal function: creatinine clearance ≥60 ml/min. 9. patients must be informed of the investigational nature of this study and give written informed consent exclusion criteria: 1. with distant metastasis. 2. who had received prior chemotherapy or radiotherapy. 3. patients have physical or mental illness, and by researchers believe that patients 4.can not be completely or fully understood in this study possible complications. 5.pregnancy (via the urine or serum β-hcg test confirmed) or during lactation. 6.serious complications, such as uncontrolled hypertension, heart failure, diabetes and so on.
study to evaluate apo805k1 in subjects with moderate to severe chronic plaque psoriasis

Conditions: Plaque Psoriasis

Summary: the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of 12 weeks of treatment with apo805k1 in subjects with moderate to severe chronic plaque psoriasis.

a) to evaluate the safety and tolerability of 12 weeks of treatment with apo805k1 b) to evaluate the pharmacokinetics of apo805k1 following daily administration for 14 days c) to evaluate the efficacy and pharmacodynamics of apo805k1

Eligibility criteria:
main inclusion criteria: * a clinical diagnosis of moderate to severe chronic plaque psoriasis for at least 6 months (before baseline assessment) with current body surface area (bsa) involvement ≥10% and psoriasis area severity index (pasi) ≥10. * male and female subjects 18 to 65 years of age, inclusive. * at least one psoriatic plaque ≥6 mm in diameter (in a location suitable for biopsy). * signed and witnessed written informed consent form obtained prior to the first study intervention, as well as the ability to adhere to study restrictions, appointments and evaluation schedule. main exclusion criteria: * treatment of psoriasis with biologic agents within 90 days prior to baseline assessment and during the study. * treatment with methotrexate, cyclosporine, retinoids, hydroxyurea or other systemic agents within 30 days prior to baseline assessment and during the study. * phototherapy within 30 days prior to baseline assessment and during the study. * psoriasis topical therapy within 14 days prior to baseline assessment and during the study (exception: non-medicated emollients and tar shampoo will be allowed). * history of liver disease or abnormal liver enzymes * serum creatinine ≥1.5 times the upper limit of normal for age and sex-matched controls. * previous treatment with apo805k1or thymodepressin or other immunosuppressant drugs. * evidence of skin conditions other than psoriasis (e.g., eczema) that could interfere with psoriasis assessments. * history of chronic infection or malignancy

Keywords: mild to moderate chronic plaque psoriasis
factors associated with the onset of chronic headaches in patients who received a blood patch in post partum

Conditions: Blood Patch; Post-Dural Puncture Headache

Summary: the purpose of this study is to identify possible links between conditions for carrying out a blood patch (bp) to treat accidental post dural puncture acute headache (pdph) in the early post partum period and occurrence of chronic headaches at 1 and 6 months.

it is established that accidental dural puncture promotes the onset of chronic headaches in 25 to 60% of cases but the risk factors for the occurrence of this event are not known. to identify those risk factors, the investigators will analyze the initial conditions of the accidental breach, the initial manifestations of the pdph, the methods of carrying out the bp and the patient data. in this study, the investigators will evaluate (phone questionnaire and score) incidence of chronic headaches at 1 month and 6 months after the realization of a blood patch, incidence of chronic low back pain, impact on daily life, incidence of late recurrences of pdph, incidence of early and distant complications in case of failure of effectiveness of the first blood patch, the investigators will search for associated factors: patient data, mode of delivery, initial pdph, conditions for carrying out the bp.

Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 years old, * vaginal delivery or caesarean section with epidural at the port royal maternity ward, * collection of non-opposition after oral and written information, exclusion criteria: * patient under curatorship or guardianship * not speaking/understanding french * bp performed in another indication * benefiting from the ame (state medical aid)

Keywords: post dural puncture headache epidural blood patch chronic headache epidural analgesia obstetric anaesthesia
analysis of body composition in relation to outcome after surgery in a cohort of patients with esophageal cancer

Conditions: Cancer of Esophagus; Gastric Cancer

Summary: the occurrence of dysphagia is a well-known early feature of esophageal cancer that may reduce caloric intake and thus cause weight loss. sarcopenia is considered to be a consequence of such involuntary nutritional restriction. the prevalence of sarcopenia in patients with esophageal cancer before and after surgery is not well known and its possible consequences have been debated. aim: the aim of this study was to prospectively explore body composition and function in a cohort of patients with esophageal cancer before and after surgery with curative intent. in particular, to investigate the prevalence and development of sarcopenia and body composition as a consequence to surgery for esophageal cancer and the possible relation to morbidity, length of stay and quality of life (qol). methods: in a cohort of 76 patients who had esophageal- or cardia-cancer and were planned for surgery with a curative intent, data on body-composition measured with bioimpedance, working capacity (cardiac stress test), grip strength and qol (european organisation for research and treatment of cancer (eortc) quality of life questionnaires (qlq)-c30 version 3.0) were prospectively collected. data regarding dysphagia was derived from an esophagus related quality of life form (eortc qlq-oes18). data on tumour stage and type, complications, length of stay and preoperative weight loss were collected from medical charts.


Eligibility criteria:
inclusion criteria: * cancer of the gastro-esophageal junction or the esophagus. * planned for curative surgery. * informed consent exclusion criteria: * not fulfilling the above. * patient declined participation.

Keywords: body composition sarcopenia dysphagia surgery quality of life morbidity
cooking classes for chinese canadian patients living with diabetes

Conditions: Diabetes Mellitus Type 2

Summary: this study aims to determine whether providing language and culturally appropriate cooking classes to chinese canadian individuals with diabetes will help to improve their diabetes control, knowledge and self care activities. the control group will receive current standard care of two diabetes education classes led by the dietitian and nurse. the intervention group will receive standard care and a series of four interactive cooking classes led by a dietitian, nurse and chef. we will compare the results of blood work, knowledge and self care questionnaires between the two groups to determine whether there are any benefits to attending these cooking classes.

this is a study attempting to investigate whether a cooking class intervention will lead to improved glycemic control in chinese-canadian people in the community of richmond, british columbia. by providing culturally appropriate cooking classes, tailored to chinese foods, culture and population, we will be able to address specific challenges that affect ethnic chinese patients with diabetes living in canada. this innovative program would serve to meet a need that is currently unmet in the community, by providing a hands-on opportunity for participants to try different foods, learn various culturally appropriate recipes, prepare meals together and learn how the foods being eaten affects blood glucose. these classes would also serve as an avenue to reinforce various diabetes self-management activities - including self-monitoring of blood glucose and the effects of physical activity. also, participants may benefit from peer support and the sharing of experiences and advice with each other. through this research study, we hope to demonstrate improved diabetes knowledge, self-care management and glycemic control for patients who attend the cooking classes.

Eligibility criteria:
inclusion criteria: 1. enrolled in type 2 diabetes education class in mandarin or cantonese at the richmond hospital diabetes education centre. 2. ability to understand and participate in all scheduled diabetes education classes and/or cooking classes; 3. ability to complete the study questionnaires and standard of care glycemic bloodwork 4. prior diagnosis of diabetes mellitus type 2 5. persons who identify as chinese-canadian exclusion criteria for this study includes: 1. inability to provide informed consent; 2. planned changes to diabetes medications during the study period, for example insulin titrations or oral medication adjustments; 3. currently enrolled in another study involving interventions related to diabetes care and management
a phase ib expansion study investigating the safety, efficacy, and pharmacokinetics of intravenous cudc-101 in subjects with advanced head and neck, gastric, breast, liver and non-small cell lung cancer tumors

Conditions: Head and Neck Cancer; Liver Cancer; Breast Cancer; Gastric Cancer; Non-Small Cell Lung Cancer

Summary: this is a phase ib open label, expansion study of cudc-101 in patients with advanced head and neck, gastric, breast, liver, and non-small cell lung cancer tumors. cudc-101 is a multi-targeted agent designed to inhibit epidermal growth factor receptor (egfr), human epidermal growth factor receptor type 2 (her2) and histone deacetylase (hdac). the study is designed to compare the safety and tolerability of cudc-101 when administered at the maximum tolerated dose on either a 5 days/week schedule or a 3 days/week schedule.


Eligibility criteria:
inclusion criteria: * subjects with histopathologically confirmed diagnosis of advanced breast, gastric, head and neck, liver and non-small cell lung cancer. * for subjects with non-small cell lung cancer only: * most recent treatment must be erlotinib and subjects must have had a radiographic partial or complete response to treatment as defined by recist criteria and should be currently progressing after the documented response. * a documented mutation in egfr exons 19 or 21 * subjects must have no further standard of care options or have refused standard therapy * measurable or evaluable disease * age ≥ 18 years * ecog performance \< 2 * life expectancy ≥ 3 months * if female, neither pregnant or lactating * if of child bearing potential, must use adequate birth control * absolute neutrophil count ≥ 1,500/µl; platelets ≥ 100,000/µl; * creatinine ≤ 1.5x upper limit of normal (uln) or calculated creatinine clearance ≥ 60ml/min/1.73m2 * total bilirubin ≤ 1.5x uln; ast/alt ≤ 2.5x uln. in subjects with documented liver metastases, the ast/alt may be ≤ 5x uln * prothrombin time ≤1.5x uln, unless receiving therapeutic anticoagulation * serum magnesium and potassium within normal limits (may use supplements to achieve normal values) * subjects with brain metastases are eligible if controlled on a stable dose ≤ 10mg prednisone/day or its equivalent dose of steroids * able to render informed consent and to follow protocol requirements. exclusion criteria: * anticancer therapy within 4 weeks of study entry. * use of investigational agent(s) within 30 days of study entry * history of cardiac disease with a new york heart association (nyha) class ii or greater congestive heart failure (chf), myocardial infarction (mi) or unstable angina in the past 6 months prior to day 1 of treatment, serious arrhythmias requiring medication for treatment. * known infection with human immunodeficiency virus (hiv), hepatitis b or hepatitis c. subjects with liver cancer and hepatitis may be eligible.

Keywords: head and neck cancer liver cancer breast cancer gastric cancer non-small cell lung cancer egfr hdac her2 cudc-101
effects of ghrelin administration on dopamine and effort

Conditions: Major Depressive Disorder

Summary: ghrelin is a stomach-derived hormone and the only known circulating peptide that stimulates appetite. animal studies have conclusively shown that ghrelin increases dopaminergic neurotransmission and, thereby, enhances effort. however, similar evidence on the putative role of ghrelin in humans is still lacking. here, the investigators propose to conduct a \[11c\]-raclopride pet/mr study after intravenous administration of ghrelin vs. saline in healthy individuals. first, during an intake visit, the investigators will assess fasting blood levels of hormones involved in appetitive behavior such as ghrelin, leptin, and insulin. in addition, the investigators will conduct a set of tasks that have been associated with dopamine function (i.e., effort and reinforcement learning). second, the investigators will assess the effects of intravenous administration of ghrelin on dopamine signaling using a double-blind randomized cross-over design. to this end, participants will be infused with ghrelin (vs. saline) while we determine dopamine release (via pet imaging) and assess cerebral blood flow and functional connectivity at rest (via concurrent mr imaging). furthermore, the investigators will conduct an instrumental motivation task (imt) where participants have to exert physical effort to obtain rewards. based on preclinical studies and indirect evidence from human studies, the investigators hypothesize that ghrelin will increase dopamine release in the striatum and that this will, in turn, lead to an increase in the willingness to work for rewards. moreover, the investigators expect that ghrelin-induced dopamine release will be associated with an elevated tracking of reward utility in the mesolimbic circuit during the imt, which is known to be associated with response vigor. collectively, the proposed project would provide a unique resource to test an important link between the gut and the brain in the regulation of appetitive behavior. if ghrelin were to enhance effort expenditure for rewards via dopamine signaling in humans, then restoring sensitivity to ghrelin might be the more promising therapeutic approach compared to antagonizing the ghrelin receptor.


Eligibility criteria:
inclusion criteria: * healthy control participants: never fulfilled the criteria of any mood or anxiety disorder (except specific phobia) * patients with major depressive disorder: diagnosis according to dsm-5 within 12 months before enrollment and presence of at least mild symptoms at enrollment (bdi ii \>= 14) exclusion criteria: * lifetime history of a brain injury, schizophrenia, bipolar disorder, and a severe substance use disorder according to dsm-5 * obsessive-compulsive disorder, trauma- and stressor-related disorder, somatic symptom disorder, and eating disorder within a 12-month interval before the test day. * neuroimaging study involving ghrelin infusion: contraindication for pet/mr (e.g., metal implants or prostheses, pregnancy, claustrophobia)

Keywords: energy homeostasis pet/mr dopamine motivation ghrelin